The National Health Regulatory Authority Bahrain (NHRA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PAXLOVID that is used in adults 18 years of age and older with mild-to-moderate COVID-19. It is only used in patients who are at high risk for progression to severe COVID-19, including hospitalisation or death.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

The patient information leaflet linked to the QR Code on the product pack has the latest updated product information approved in your country, which may be more up to date than the paper leaflet.

Read the PAXLOVID™ Package Leaflet: Information for the Patient

نشرة العبوة: معلومات للمريض